Chemotherapy Can Interfere in Implantation in In-vitro Fertilization

Area of Science:

• Reproductive medicine and oncology
• Hematology and cancer therapy

Background:

• Cancer survivors increasingly seek pregnancy post-treatment.
• Chemotherapy's impact on ovaries is known, but uterine effects on embryo implantation are unclear.
• Tyrosine kinase inhibitors like nilotinib are vital for leukemia treatment.

Observation:

• A patient with a history of four failed in-vitro fertilization (IVF) attempts while on nilotinib presented for further treatment.
• Despite meeting criteria for optimal endometrial thickness and receptivity, hysteroscopy revealed a pale endometrium, suspected to be a nilotinib side effect.
• Nilotinib was withheld before the subsequent embryo transfer.

Findings:

• The patient achieved a successful pregnancy after nilotinib cessation prior to embryo transfer.
• This outcome suggests nilotinib may adversely affect endometrial receptivity and embryo implantation.
• The pale endometrial appearance on hysteroscopy was a key indicator prompting nilotinib's discontinuation.

Implications:

• Discontinuing nilotinib before embryo transfer may be a viable strategy to improve IVF success rates in specific patient populations.
• Further research is warranted to elucidate the precise mechanisms by which nilotinib affects endometrial receptivity.
• This case highlights the importance of considering drug effects on fertility and pregnancy outcomes in cancer survivors.